XENON PHARMACEUTICALS INC. Debt Securities, Available-for-sale, Amortized Cost, Noncurrent
XENON PHARMACEUTICALS INC. (XENE) had Debt Securities, Available-for-sale, Amortized Cost, Noncurrent of $315.41 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Debt Securities, Available-for-Sale, Amortized Cost
us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost, Noncurrent $315.41M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost, Noncurrent $244.97M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost, Noncurrent $36.88M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost, Noncurrent |
|---|---|
| 2026-06-30 | $315.41M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $244.97M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $36.88M 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |